𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Sublingual captopril — a pharmacokinetic and pharmacodynamic evaluation

✍ Scribed by T. A. Al-Furaih; J. C. McElnay; J. S. Elborn; R. Rusk; M. G. Scott; J. McMahon; D. P. Nicholls


Publisher
Springer
Year
1991
Tongue
English
Weight
515 KB
Volume
40
Category
Article
ISSN
0031-6970

No coin nor oath required. For personal study only.

✦ Synopsis


In this study we compared the pharmacokinetics and pharmacodynamics of captopril after sublingual and peroral administration. Single 25 mg doses of captopril were administered sublingually and perorally on two different occasions in a randomised cross-over fashion to eight healthy volunteers aged 22-35 years. The kinetics of unchanged captopril, plasma renin activity (PRA). BP and heart rate were studied over three hours after both peroral and sublingual administration of captopril. Mean pharmacokinetic parameters for unchanged captopril after sublingual administration were: Cmax, 234 ng.ml-1; tmax, 45 min; AUC (0-3 h), 15.1 micrograms.ml-1.min. Mean pharmacokinetic parameters for unchanged captopril after peroral administration were; Cmax, 228 ng.ml-1; tmax, 75 min; AUC (0-3 h), 17.0 micrograms.ml-1.min.tmax was significantly shorter when captopril was administered sublingually; all other pharmacokinetic parameters were equivalent. The plasma captopril concentrations achieved post drug administration led to increases in PRA and reductions in BP.tmax for PRA was 86 min for sublingual captopril and 113 min for perorally administered drug. Peak PRA values were, however, not significantly different. BP, as expected, was not reduced dramatically in these healthy volunteer subjects, however, in systolic BP vs time profiles, BP was significantly lower after volunteers received sublingual captopril. Heart rate increased slightly after captopril administration; there were no differences between the two routes of administration. Administration of captopril sublingually, therefore led to a more rapid attainment of plasma captopril concentrations and had a more rapid onset of pharmacological effect when compared with peroral administration.


📜 SIMILAR VOLUMES


A pharmacokinetic and pharmacodynamic ev
✍ J. C. McElnay; T. A. Al-Furaih; C. M. Hughes; M. G. Scott; D. P. Nicholls 📂 Article 📅 1996 🏛 Springer 🌐 English ⚖ 538 KB

Objective: The pharmacokinetics and pharmacodynamics of buffered sublingual captopril were assessed in patients with congestive heart failure (CHF). Methods: The study was carried out in a randomised single-blind cross-over fashion (n = 6, 4 males and 2 females) and involved two study days, at least

Daytime pharmacodynamic and pharmacokine
✍ Thomas Roth; David Mayleben; Bruce C. Corser; Nikhilesh N. Singh 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 177 KB

## Abstract ## Objectives Buffered low‐dose sublingual transmucosal zolpidem lozenge hemitartrate (ST zolpidem) is being developed for the treatment of middle‐of‐the‐night insomnia. The objective of this double‐blind placebo‐controlled cross‐over study (__n__ = 24) was to evaluate the pharmacokine

PHARMACOKINETIC–PHARMACODYNAMIC MODELLIN
✍ Conrad M. Pereira; Yun K. Tam; James Y. Coe; Peter M. Olley; Ruth L. Collins-Nak 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 441 KB

The use of the angiotensin converting enzyme inhibitor, captopril, specially in children, has been empirical. This is because the relationship between the pharmacokinetics and pharmacodynamics of captopril has not been clearly defined. It is not usually feasible to obtain the serial kinetic-dynamic

Pharmacokinetic and pharmacodynamic eval
✍ Oliver Ghobrial; Hartmut Derendorf; Jeffrey D. Hillman 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 166 KB

Presented are the pharmacokinetics (PK), exposure-response relationship, and the PK/pharmacodynamic (PD) index predictive of maximum therapeutic efficacy for the lantibiotic MU1140. MU1140, at a dose of 12.5 or 25 mg/kg, was administered intravenously, to characterize its PK parameters in rat. The r

A rabbit model for sublingual drug deliv
✍ Dali, Manisha M. (author);Moench, Paul A. (author);Mathias, Neil R. (author);Ste 📂 Article 📅 2006 🏛 John Wiley and Sons Inc. 🌐 English ⚖ 109 KB

A rabbit model for investigating sublingual drug absorption was established yielding results consistent with clinical data reported in the literature. Using propranolol as a model compound the effect of formulation and dosing variables was explored as a means to characterize the limiting parameters